Lifecore Biomedical, Inc. (LFCR) SEC filings

LFCRNasdaqPharmaceutical PreparationsFiscal year ends May 25

Financials through Q3 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30

$6.42+0.02 (+0.31%)

Close on Nov 13, 2026Market cap $243.02MP/E –Yield –

SEC filings

40 of Lifecore Biomedical's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Nov 4, 2026	Nov 5, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2026	Nov 4, 2026	SEC EDGAR
Current report	8-K	Nov 4, 2026	Nov 4, 2026	SEC EDGAR
Current report	8-K	Oct 16, 2026	Oct 20, 2026	SEC EDGAR
Current report	8-K	Sep 24, 2026	Sep 29, 2026	SEC EDGAR
Current report	8-K	Sep 27, 2026	Sep 28, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 5, 2026	SEC EDGAR
Current report	8-K	Aug 5, 2026	Aug 5, 2026	SEC EDGAR
Current report	8-K	Jun 29, 2026	Jul 2, 2026	SEC EDGAR
Current report	8-K	Jun 4, 2026	Jun 5, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 6, 2026	SEC EDGAR
Current report	8-K	May 6, 2026	May 6, 2026	SEC EDGAR
Proxy statement	DEF 14A	Apr 24, 2026	Apr 24, 2026	SEC EDGAR
Current report	8-K	Mar 16, 2026	Mar 16, 2026	SEC EDGAR
Current report	8-K	Mar 5, 2026	Mar 5, 2026	SEC EDGAR
Current report	8-K	Jan 14, 2026	Jan 16, 2026	SEC EDGAR
Current report	8-K	Nov 17, 2025	Nov 17, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 6, 2025	SEC EDGAR
Current report	8-K	Nov 6, 2025	Nov 6, 2025	SEC EDGAR
Current report	8-K	Oct 29, 2025	Oct 31, 2025	SEC EDGAR
Current report	8-K	Sep 22, 2025	Sep 26, 2025	SEC EDGAR
Proxy statement	DEF 14A	Sep 18, 2025	Sep 18, 2025	SEC EDGAR
Current report	8-K	Aug 12, 2025	Aug 18, 2025	SEC EDGAR
Current report	8-K	Aug 12, 2025	Aug 12, 2025	SEC EDGAR
Annual report	10-K	May 25, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	Aug 7, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	Jul 15, 2025	Jul 18, 2025	SEC EDGAR
Current report	8-K	Apr 11, 2025	Apr 16, 2025	SEC EDGAR
Current report	8-K	Apr 10, 2025	Apr 10, 2025	SEC EDGAR
Quarterly report	10-Q	Feb 23, 2025	Apr 3, 2025	SEC EDGAR
Current report	8-K	Apr 3, 2025	Apr 3, 2025	SEC EDGAR
Proxy statement	DEF 14A	Feb 27, 2025	Feb 27, 2025	SEC EDGAR
Current report	8-K	Jan 17, 2025	Jan 17, 2025	SEC EDGAR
Current report	8-K	Jan 7, 2025	Jan 7, 2025	SEC EDGAR
Quarterly report	10-Q	Nov 24, 2024	Jan 2, 2025	SEC EDGAR
Current report	8-K	Jan 2, 2025	Jan 2, 2025	SEC EDGAR
Current report	8-K	Nov 26, 2024	Nov 26, 2024	SEC EDGAR
Current report	8-K	Nov 21, 2024	Nov 21, 2024	SEC EDGAR
Current report	8-K	Nov 7, 2024	Nov 8, 2024	SEC EDGAR
Quarterly report	10-Q	Aug 25, 2024	Oct 4, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Lifecore Biomedical's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is LFCR.

Compare: LFCR vs MRVI · LFCR vs ELTP · LFCR vs HRTX · LFCR vs RMTI · LFCR vs CYRX

Revenue growth0.5% · median 10.7%

Gross margin31.3% · median 43.7%

Operating margin-13.4% · median -7.1%

Net margin-30.0% · median -14.5%

Company	Revenue	Growth
MRVI	$213.00M	+10.7%
CYRX	$192.44M	+11.8%
HRTX	$148.22M	-4.4%
ELTP	$144.77M	+17.8%
LFCR	$128.87M	+0.5%
RMTI	$72.58M	-4.0%

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: May 25
Employees: 382
Held by institutions: 67.1%
Auditor: KPMG LLP
SEC CIK: 1005286

Advertisement
300 × 250

See a number that looks wrong?